Originally published by our sister publication Infectious Disease Special Edition
By Ethan Covey
Cabotegravir and rilpivirine (CAB+RPV; Cabenuva, ViiV Healthcare) long-acting injections are effective at controlling HIV, with 96% of users maintaining a viral load of less than 200 copies/mL, according to data presented at IDWeek 2023, in Boston (poster 1608).
Additionally, 94% of people receiving CAP+RPV had a viral load of less than 50 copies/mL at their last measured follow-up.
“CAB+RPV